Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
暂无分享,去创建一个
Junfeng Xia | Peilin Jia | William Pao | Zhongming Zhao | Franziska Michor | Hailing Jin | Zhongming Zhao | P. Jia | W. Pao | K. Politi | F. Michor | Hailing Jin | V. Pirazzoli | Junfeng Xia | Lin L. Liu | K. Dahlman | K. Ohashi | Valentina Pirazzoli | Katerina Politi | C. Meador | Lin Liu | Kimberly B Dahlman | Kadoaki Ohashi | Catherine B Meador | Zhongming Zhao
[1] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[2] S. De,et al. DNA replication timing and higher-order nuclear organization determine single nucleotide substitution patterns in cancer genomes , 2013, Nature Communications.
[3] Terrence S. Furey,et al. The UCSC Genome Browser Database , 2003, Nucleic Acids Res..
[4] David Haussler,et al. Integration of the cytogenetic map with the draft human genome sequence. , 2003, Human molecular genetics.
[5] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[6] Cole Trapnell,et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.
[7] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[8] Michael O Dorschner,et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing , 2009, Proceedings of the National Academy of Sciences.
[9] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[10] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[11] Thomas D. Wu,et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.
[12] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[13] L. Wessels,et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions , 2008, Nature.
[14] Niruthika Sritharan,et al. Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.
[15] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[16] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[17] Emmanuel Barillot,et al. Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization , 2010, Bioinform..
[18] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[19] Derek Y. Chiang,et al. High-resolution mapping of copy-number alterations with massively parallel sequencing , 2009, Nature Methods.
[20] John Quackenbush,et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV , 2011, Bioinform..
[21] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[22] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[23] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[24] Bin Tean Teh,et al. Assessing Matched Normal and Tumor Pairs in Next-Generation Sequencing Studies , 2011, PloS one.
[25] Olivier Elemento,et al. Using transcriptome sequencing to identify mechanisms of drug action and resistance , 2011, Nature chemical biology.
[26] William Pao,et al. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.
[27] Vincent J Carey,et al. Bioconductor: an open source framework for bioinformatics and computational biology. , 2006, Methods in enzymology.
[28] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[29] Lior Pachter,et al. Sequence Analysis , 2020, Definitions.
[30] William Pao,et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 , 2012, Proceedings of the National Academy of Sciences.
[31] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[32] D. Gudbjartsson,et al. A high-resolution recombination map of the human genome , 2002, Nature Genetics.
[33] Fang Fang,et al. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution , 2011, Bioinform..
[34] Y. Yatabe,et al. Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[36] J. Jurka. Repbase update: a database and an electronic journal of repetitive elements. , 2000, Trends in genetics : TIG.
[37] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[38] Bradley P. Coe,et al. Copy number variation detection and genotyping from exome sequence data , 2012, Genome research.
[39] Antony V. Cox,et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.
[40] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[41] Junfeng Xia,et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.
[42] Tatiana Popova,et al. Supplementary Methods , 2012, Acta Neuropsychiatrica.
[43] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[44] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[45] A. Feinberg,et al. A species-generalized probabilistic model-based definition of CpG islands , 2009, Mammalian Genome.
[46] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[47] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .